RxDoctor Payments DataLook up a doctor →

Andrew Peranteau, MD

Dermatology · New York, NYNPI 1588075386

Payments from drug & device makers

$746,175in general payments, 2019–2025

Across 783 payments — averaging $952.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$252K
  • Kiniksa Pharmaceuticals, Ltd.$226K
  • Pfizer$95K
  • Sun Pharmaceutical Industries Inc.$45K
  • AbbVie$29K
  • Avita Medical Americas, LLC$27K
  • plus $72K from 28 others

What the payments were for

  • Consulting fees$2,2757%
  • Speaking & faculty fees$14,95049%
  • Travel & lodging$5992%
  • Food & beverage$12,51041%
  • Education$2051%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$746,175 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$59,871
Medicare patients
162
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate14$27,486
Acitretin11$3,190
Tretinoin34$2,579
Clobetasol Propionate40$1,849
Metronidazole19$1,648
Halobetasol Propionate25$1,643
Clindamycin Phosphate29$1,177
Ketoconazole95$1,134
Ammonium Lactate40$806
CiclopiroxCiclopirox Olamine11$764
Fluocinonide22$680
Triamcinolone Acetonide69$502
Azelaic Acid11$391
Hydrocortisone16$250
Spironolactone14$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$252,067$27,48614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →